Literature DB >> 33034812

Quality of life more than 10 years after radiotherapy for localized prostate cancer-impact of time after treatment and prescription dose.

Michael Pinkawa1,2, Amr Gharib3, Marsha Schlenter3, Ludmila Timm3,4, Michael J Eble3.   

Abstract

PURPOSE: Analysis of quality of life changes after radiotherapy with focus on the impact of time after treatment and prescription dose.
METHODS: Consecutive patients were treated with doses from 70.2/1.8 Gy (n = 206) to 72/1.8-2.0 Gy (n = 176) in a single centre and surveyed using the Expanded Prostate Cancer Index Composite questionnaire.
RESULTS: Urinary and bowel bother scores decreased 1 / 3 / 6 points and 7 / 7 / 9 points on average 1 / 5 / 10 years after RT in comparison to baseline scores. The rate of urinary (need of pads in 8% vs. 15% before vs. 10 years after RT; p = 0.01) and bowel (uncontrolled leakage of stool in 5% vs. 12% before vs. 10 years after RT; p < 0.01) incontinence, as well as rectal bleeding (4% vs. 8% before vs. 10 years after RT; p = 0.05) increased. Sexual function scores decreased (erections sufficient for intercourse in 36% vs. 12% before vs. 10 years after RT; p < 0.01). A higher dose had a statistically significant impact on urinary bother and stool incontinence, but also tended to decrease urinary continence. Age and comorbidities did not have an influence on score changes, but on baseline urinary function/bother and baseline sexual function.
CONCLUSION: Apart from an increasing rate of erectile dysfunction, urinary and bowel incontinence rates increased with increasing follow-up period. A higher dose was found to be associated with increased urinary problems and larger stool incontinence rates. Age and comorbidities were found to be relevant for baseline scores, but not for score changes.

Entities:  

Keywords:  Conformal radiotherapy; Dose–response relationship; Prostate neoplasms; Quality of life

Mesh:

Year:  2020        PMID: 33034812      PMCID: PMC7886756          DOI: 10.1007/s11136-020-02639-7

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   3.440


  20 in total

1.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Authors:  Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-15       Impact factor: 7.038

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

3.  Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT : Clinical results and quality of life.

Authors:  Marsha Schlenter; Vanessa Berneking; Barabara Krenkel; Felix M Mottaghy; Thomas-Alexander Vögeli; Michael J Eble; Michael Pinkawa
Journal:  Strahlenther Onkol       Date:  2018-03-06       Impact factor: 3.621

4.  Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy : TROD 09-001 multi-institutional study.

Authors:  Gokhan Ozyigit; Cem Onal; Sefik Igdem; Zumre Arican Alicikus; Ayca Iribas; Mustafa Akin; Deniz Yalman; Ilknur Cetin; Melek Gamze Aksu; Banu Atalar; Fazilet Dincbas; Pervin Hurmuz; Ozan Cem Guler; Barbaros Aydin; Fatma Sert; Cumhur Yildirim; Ilknur Birkay Gorken; Fulya Yaman Agaoglu; Aylin Fidan Korcum; Deniz Yuce; Serdar Ozkok; Emin Darendeliler; Fadil Akyol
Journal:  Strahlenther Onkol       Date:  2019-05-29       Impact factor: 3.621

5.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.

Authors:  J T Wei; R L Dunn; M S Litwin; H M Sandler; M G Sanda
Journal:  Urology       Date:  2000-12-20       Impact factor: 2.649

6.  Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?

Authors:  Deborah A Kuban; Lawrence B Levy; M Rex Cheung; Andrew K Lee; Seungtaek Choi; Steven Frank; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-05-20       Impact factor: 7.038

7.  Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.

Authors:  Michael Pinkawa; Marc D Piroth; Richard Holy; Victoria Djukic; Jens Klotz; Barbara Krenkel; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2011-07-25       Impact factor: 3.621

8.  Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.

Authors:  Kazuro Kikkawa; Akinori Iba; Yasuo Kohjimoto; Yasutaka Noda; Tetsuo Sonomura; Isao Hara
Journal:  Int J Urol       Date:  2018-02-04       Impact factor: 3.369

Review 9.  Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.

Authors:  Gustavo Arruda Viani; Eduardo Jose Stefano; Sergio Luis Afonso
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-01       Impact factor: 7.038

10.  ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer.

Authors:  Pirus Ghadjar; Claudio Fiorino; Per Munck Af Rosenschöld; Michael Pinkawa; Thomas Zilli; Uulke A van der Heide
Journal:  Radiother Oncol       Date:  2019-10-23       Impact factor: 6.280

View more
  2 in total

Review 1.  A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy.

Authors:  Gianluca Ferini; Stefano Pergolizzi
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

2.  Late Adverse Health Outcomes and Quality of Life after curative radiotherapy + long-term ADT in Prostate Cancer Survivors: Comparison with men from the general population.

Authors:  Sophie D Fosså; Alv A Dahl; Tom Børge Johannesen; Ylva M Gjelsvik; Anne Holck Storås; Tor Å Myklebust
Journal:  Clin Transl Radiat Oncol       Date:  2022-08-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.